On January 3, 2023 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, reported the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for HST-1011, the Company’s investigational small molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B) (Press release, HotSpot Therapeutics, JAN 3, 2023, View Source [SID1234625763]). This represents the first IND filing for HotSpot. The Company expects to initiate the Phase 1/2 study of HST-1011 in the first quarter of 2023, with an initial focus on the evaluation of HST-1011 as monotherapy in patients with advanced solid tumors who are relapsed or refractory to anti-PD(L)1 therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Clearance of our first IND is an important step forward for our Smart Allostery platform and our mission to produce a pipeline of differentiated product candidates for clinically meaningful, yet historically difficult-to-drug, targets," said Tim Reilly, Ph.D., Chief Development Officer of HotSpot Therapeutics. "Despite tremendous advances in the field of immuno-oncology (I-O), a significant unmet need persists for patients with tumors that either do not respond to or relapse following treatment with existing immunotherapies. With robust preclinical data supporting the potential of CBL-B inhibition to create an immunostimulatory tumor microenvironment and in turn, address the underlying factors that serve as a basis for poor response, we believe the therapeutic advancement of CBL-B inhibition represents a significant turning point for I-O."
About HST-1011
HST-1011 is an investigational orally bioavailable, selective, small molecule allosteric inhibitor of CBL-B, an E3 ubiquitin protein ligase critically involved in immune cell response. Because CBL-B functions as a master regulator of effector cell (T cell and natural killer cell) immunity, its inactivation removes its endogenous negative regulatory functions to substantially enhance anti-tumor immunity. Preclinical data has demonstrated HST-1011’s ability to bind to and inhibit a natural hotspot on CBL-B, yielding the activation and propagation of a targeted anti-tumor immune response. Enabled by HotSpot’s proprietary Smart Allostery platform, HST-1011 is designed with tight binding, low nanomolar potency, a slow dissociation rate from the target to enable sustained pharmacology, and greater selectivity for CBL-B relative to C-CBL.